Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2026)

Recursion Pharmaceuticals' Receivables - Other history runs 6 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• Quarterly Receivables - Other fell 70.55% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (down 70.55% YoY) and the FY2025 annual result came in at $24.6 million, down 49.87% from the prior year.
• Receivables - Other was $13.6 million for Q1 2026 at Recursion Pharmaceuticals, down from $24.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $49.2 million in Q4 2024 and bottomed at $2.1 million in Q1 2023.
• A 5-year average of $14.2 million and a median of $11.4 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other tumbled 81.9% — and 2025, when it soared 1674.68%.
• Recursion Pharmaceuticals' Receivables - Other stood at $2.8 million in 2022, then rose by 12.39% to $3.1 million in 2023, then jumped by 1489.08% to $49.2 million in 2024, then tumbled by 49.87% to $24.6 million in 2025, then plunged by 44.89% to $13.6 million in 2026.
• Business Quant data shows RXRX's Receivables - Other at $13.6 million in Q1 2026, $24.6 million in Q4 2025, and $21.9 million in Q3 2025.